Now showing items 1-6 of 6

    • Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. 

      Webster, Lucy; Groskreutz, Derek; Grinbergs-Saull, Anna; Howard, Rob; O'Brien, John Tiernan; Mountain, Gail; Banerjee, Sube et al. (2017-05)
      BACKGROUND: There is currently no disease-modifying treatment available to halt or delay the progression of the disease pathology in dementia. An agreed core set of the best-available and most appropriate outcomes for ...
    • DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT 

      Jones, Rob; Sheehan, Bart; Phillips, Patrick; Juszczak, Ed; Adams, Jessica; Baldwin, Ashley; Ballard, Clive et al. (2009-07-24)
      Abstract Background Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while ...
    • Intensive versus Guideline Blood Pressure and Lipid Lowering in Patients with Previous Stroke: Main Results from the Pilot 'Prevention of Decline in Cognition after Stroke Trial' (PODCAST) Randomised Controlled Trial. 

      Bath, Philip M; Scutt, Polly; Blackburn, Daniel J; Ankolekar, Sandeep; Krishnan, Kailash; Ballard, Clive; Burns, Alistair et al. (Public Library of Science (PLoS), 2017-01-17)
      Background: Stroke is associated with the development of cognitive impairment and dementia. We assessed the effect of intensive blood pressure (BP) and/or lipid lowering on cognitive outcomes in patients with recent stroke ...
    • Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia. 

      Alghamdi, Amani; Vallortigara, Julie; Howlett, David R; Broadstock, Martin; Hortobágyi, Tibor; Ballard, Clive; Thomas, Alan J et al. (IOS Press, 2017-01)
      Lewy body dementia is the second most common neurodegenerative dementia and is pathologically characterized by $\alpha$-synuclein positive cytoplasmic inclusions, with varying amounts of amyloid-$\beta$ (A$\beta$) and ...
    • Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias 

      Howlett, David R; Whitfield, David; Johnson, Mary; Attems, Johannes; O’Brien, John T; Aarsland, Dag; Lai, Mitchell KP et al. (Wiley, 2014-10-30)
      Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) are characterized by the presence of α-synuclein-containing Lewy bodies and Lewy neurites. However, both dementias also show variable degrees of ...
    • A roadmap to advance dementia research in prevention, diagnosis, intervention, and care by 2025. 

      Pickett, James; Bird, Cathy; Ballard, Clive; Banerjee, Sube; Brayne, Carol Elspeth; Cowan, Katherine; Clare, Linda et al. (Wiley-Blackwell, 2018-02-22)
      Objective: National and global dementia plans have focused on the research ambition to develop a cure or disease-modifying therapy by 2025, with the initial focus on investment in drug discovery approaches. We set out to ...